◎ Sugi Atlas

Atlas / Drug / Celecoxib

Celecoxib

drug
On this page

Also known as CelebrexCelecoxib component of consensiCelecoxib component of seglentisCelebraDFN-15DFN15ElyxybNSC-719627NSC-758624OnsenalSC-58635SID17389545CelecoxibeSID49665790SID26747363SID49666478SID535138SID124890934SID144204686

Summary

Celecoxib (CHEMBL118) is an approved small-molecule non-narcotic analgesic (ATC M01AH01) targeting PTGS1, PTGS2, and CA12; indicated across 117 conditions including ankylosing spondylitis and juvenile idiopathic arthritis; with CIViC clinical evidence for 3 variant-indication associations (e.g. COX2 Overexpression in her2-receptor negative breast cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: M01AH01 (+1 more)
  • Targets: 3 (PTGS1, PTGS2, CA12)
  • Indications: 117 conditions
  • Clinical trials: 499
  • Precision-oncology evidence (CIViC): 3 variant–indication associations
  • Chemistry: 381.4 Da · C17H14F3N3O2S

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL118
NameCelecoxib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID2662
ChEBICHEBI:41423
ATCM01AH01, L01XX33
Molecular formulaC17H14F3N3O2S
Molecular weight381.4
InChIKeyRZEKVGVHFLEQIL-UHFFFAOYSA-N

SMILES: CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F

IUPAC name: 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide

ChEBI definition: A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-sulfamoylphenyl, trifluoromethyl and p-tolyl groups, respectively. A cyclooxygenase-2 inhibitor, it is used in the treatment of arthritis.

Pharmacological roles (ChEBI): non-narcotic analgesic, cyclooxygenase 2 inhibitor, geroprotector, non-steroidal anti-inflammatory drug.

Also known as: Celebrex, Celecoxib, Celecoxib component of consensi, Celecoxib component of seglentis, Celebra, DFN-15, DFN15, Elyxyb, NSC-719627, NSC-758624, Onsenal, SC-58635

Parent form; salt/anhydrous children: CHEMBL395268, CHEMBL1801594

Patent coverage: 27,749 distinct patent families (112,844 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PTGS1COX-1Inhibition4.820%P23219
PTGS2COX-2Inhibition6.520%P35354
CA12carbonic anhydrase 12Inhibition7.740.2%O43570

Broader ChEMBL bioactivity targets: 62 (assay-derived). Sample: Cytochrome c oxidase subunit 2, Prelamin-A/C, cGMP-specific 3’,5’-cyclic phosphodiesterase, Protein deacetylase HDAC6, Alpha-2B adrenergic receptor, Thyrotropin receptor, Equilibrative nucleoside transporter 1, Carbonic anhydrase 2, D(1A) dopamine receptor, Histone deacetylase.

Bioactivity

ChEMBL activities: 511 potent at pChembl ≥ 5 of 717 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
PTGS29.33Ki0.47nMCHEMBL_ACT_23150712
Q057699.29IC500.51nMCHEMBL_ACT_2539030
PTGS29.28IC500.52nMCHEMBL_ACT_2234764
PTGS29.28IC500.52nMCHEMBL_ACT_2234795
P224379.15IC500.7nMCHEMBL_ACT_36227
PTGS28.7IC502nMCHEMBL_ACT_774626
PTGS28.7IC502nMCHEMBL_ACT_876569
PTGS28.7IC502nMCHEMBL_ACT_877100
PTGS28.7IC502nMCHEMBL_ACT_997132
PTGS28.66IC502.2nMCHEMBL_ACT_1760998
Q057698.49IC503.2nMCHEMBL_ACT_23150850
Q057698.49IC503.2nMCHEMBL_ACT_23150854
P059798.43IC503.7nMCHEMBL_ACT_1760997
PTGS28.32IC504.8nMCHEMBL_ACT_18136961
PTGS28.22IC506nMCHEMBL_ACT_1610388
PTGS28.22IC506nMCHEMBL_ACT_23305828
PTGS28.17IC506.8nMCHEMBL_ACT_1610389
PTGS28.15IC507nMCHEMBL_ACT_18241968
Q057698.06IC508.7nMCHEMBL_ACT_14569696
Q057698.03IC509.3nMCHEMBL_ACT_36226
PTGS28IC5010nMCHEMBL_ACT_6168012
PTGS27.99IC5010.25nMCHEMBL_ACT_25034798
PTGS27.95IC5011.2nMCHEMBL_ACT_19097395
PTGS27.92IC5012nMCHEMBL_ACT_18469610
PTGS27.91IC5012.2nMCHEMBL_ACT_24709480
PTGS17.89IC5013nMCHEMBL_ACT_25022353
CA97.83Ki14.8nMCHEMBL_ACT_24686249
PTGS27.82IC5015nMCHEMBL_ACT_25724885
PTGS27.8IC5016nMCHEMBL_ACT_15246373
CA97.8IC5016nMCHEMBL_ACT_1614182

Target pathways

Aggregated over 3 target gene(s): PTGS1, PTGS2, CA12.

Top Reactome pathways

11 total, by targets touching each:

PathwayTargetsGenes
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)2PTGS1, PTGS2
COX reactions1PTGS1
Metabolism1CA12
Reversible hydration of carbon dioxide1CA12
Synthesis of 15-eicosatetraenoic acid derivatives1PTGS2
Interleukin-10 signaling1PTGS2
Interleukin-4 and Interleukin-13 signaling1PTGS2
Biosynthesis of DHA-derived SPMs1PTGS2
Biosynthesis of EPA-derived SPMs1PTGS2
Biosynthesis of DPAn-3 SPMs1PTGS2
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives1PTGS2

Dominant GO biological processes

GO termTargets
prostaglandin biosynthetic process2
response to oxidative stress2
regulation of blood pressure2
cyclooxygenase pathway2
regulation of cell population proliferation2
long-chain fatty acid biosynthetic process2
lipid metabolic process2
fatty acid metabolic process2
fatty acid biosynthetic process2
prostaglandin metabolic process2
prostanoid biosynthetic process2
cellular oxidant detoxification2
embryo implantation1
response to nematode1
response to selenium ion1

Indications & clinical

Indications

117 indications (18 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
ankylosing spondylitis4MONDO:0005306EFO:0003898
juvenile idiopathic arthritis4MONDO:0011429EFO:0002609
rheumatoid arthritis4MONDO:0008383EFO:0000685
neoplasm4MONDO:0005070EFO:0000616
rheumatic disorder4MONDO:0005554EFO:0005755
colorectal neoplasm4MONDO:0005335EFO:0004142
peptic ulcer disease4MONDO:0004247HP:0004398
stroke disorder4MONDO:0005098EFO:0000712
spondylitis4MONDO:0003937MONDO:0003937
osteoarthritis4MONDO:0005178MONDO:0005178
migraine disorder4MONDO:0005277MONDO:0005277
breast carcinoma3MONDO:0004989EFO:0000305
osteoarthritis, knee3MONDO:0005416EFO:0004616
gout3MONDO:0005393EFO:0004274
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
hypertensive disorder3MONDO:0005044EFO:0000537
colorectal adenoma3MONDO:0005484EFO:0005406
nicotine dependence3MONDO:0008575EFO:0003768
osteoarthritis, hip3MONDO:0006629EFO:1000786
injury3MONDO:0021178EFO:0000546
exocrine pancreatic carcinoma3MONDO:0005192EFO:0002618
breast neoplasm3MONDO:0021100EFO:0003869
colonic neoplasm3MONDO:0005401EFO:0004288
head and neck cancer3MONDO:0005627EFO:0006859
postpartum depression3MONDO:0005929EFO:0007453
rectal cancer3MONDO:0006519EFO:1000657
colon carcinoma3MONDO:0002032EFO:1001950
colorectal carcinoma3MONDO:0024331EFO:1001951
macular degeneration3MONDO:0003004EFO:0009606
colorectal adenocarcinoma3MONDO:0005008EFO:0000365
influenza3MONDO:0005812EFO:0007328
pharyngitis3MONDO:0002258MONDO:0002258
lung neoplasm3MONDO:0021117MONDO:0008903
rectal neoplasm3MONDO:0002165MONDO:0044937
hand-foot syndrome3MONDO:0700048EFO:1001893
depressive disorder3MONDO:0002050MONDO:0002050
Alzheimer disease3MONDO:0004975MONDO:0004975
bipolar disorder3MONDO:0004985MONDO:0004985
subacute thyroiditis3MONDO:0006982EFO:1001194
nasopharyngeal carcinoma3MONDO:0015459MONDO:0015459
preeclampsia2MONDO:0005081EFO:0000668
benign prostatic hyperplasia2MONDO:0010811EFO:0000284
prostate adenocarcinoma2MONDO:0005082EFO:0000673
monoclonal gammopathy2MONDO:0004960EFO:0000203
glioblastoma2MONDO:0018177EFO:0000519
renal cell carcinoma2MONDO:0005086EFO:0000681
sarcoma2MONDO:0005089EFO:0000691
ovarian carcinoma2MONDO:0005140EFO:0001075
plasma cell myeloma2MONDO:0009693EFO:0001378
medulloblastoma2MONDO:0007959EFO:0002939
ovarian neoplasm2MONDO:0021068EFO:0003893
temporomandibular joint disorder2MONDO:0005473EFO:0005279
neuralgia2MONDO:0021667EFO:0005762
stomatitis2MONDO:0004842EFO:1001904
melanoma2MONDO:0005105EFO:0000756
spinal muscular atrophy2MONDO:0001516EFO:0008525
rotator cuff syndrome2MONDO:0007028EFO:1001250
central nervous system neoplasm2MONDO:0006130EFO:1000158
brain cancer2MONDO:0001657MONDO:0001657
peritoneal neoplasm2MONDO:0006901MONDO:0002087
papilloma2MONDO:0002363MONDO:0002363
uterine cancer2MONDO:0002715MONDO:0002715
ovarian cancer2MONDO:0008170MONDO:0008170
oral cavity squamous cell carcinoma2MONDO:0004958EFO:0000199
obsessive-compulsive disorder2MONDO:0008114EFO:0004242
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
chronic hepatitis B virus infection2MONDO:0005366EFO:0004239
intracerebral hemorrhage2MONDO:0013792EFO:0005669
amyotrophic lateral sclerosis2MONDO:0004976MONDO:0004976
lymphangioleiomyomatosis2MONDO:0011705MONDO:0011705
neurofibromatosis type 12MONDO:0018975MONDO:0018975
dysplasia of cervix2MONDO:0006736MONDO:0042487
paraganglioma2MONDO:0000448EFO:1000453
tonsillitis2MONDO:0001039MONDO:0001039
multiple sclerosis2MONDO:0005301MONDO:0005301
endometrium neoplasm2MONDO:0021251MONDO:0011962
long COVID-192MONDO:0100233MONDO:0100233
oral cavity neoplasm1MONDO:0021245EFO:0003868
cervical adenocarcinoma1MONDO:0005153EFO:0001416
hepatocellular carcinoma1MONDO:0007256EFO:0000182
neuroblastoma1MONDO:0005072EFO:0000621
orthostatic hypotension1MONDO:0005469EFO:0005252
actinic keratosis1MONDO:0005173EFO:0002496
breast carcinoma in situ1MONDO:0004658MONDO:0004658
Wilson disease1MONDO:0010200MONDO:0010200
tuberculosis1MONDO:0018076MONDO:0018076
bone fracture1MONDO:0005315EFO:0003931
triple-negative breast carcinoma1MONDO:0005494EFO:0005537
myositis disease1MONDO:0021167EFO:0000783
anti-neutrophil antibody associated vasculitis1MONDO:0005435EFO:0004826
obesity disorder0MONDO:0011122EFO:0001073
major depressive disorder0MONDO:0002009MONDO:0002009

25 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 499.

Phase distribution

PhaseTrials
PHASE2156
PHASE492
PHASE385
PHASE175
Not specified49
PHASE1/PHASE224
PHASE2/PHASE39
EARLY_PHASE19

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04147013PHASE4ACTIVE_NOT_RECRUITINGEffect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS
NCT05488847PHASE4ACTIVE_NOT_RECRUITINGOpioid-Free Pain Protocol After Shoulder Arthroplasty
NCT06245109PHASE4RECRUITINGBrain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis
NCT06379425PHASE4RECRUITINGImpact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries
NCT06699966PHASE4NOT_YET_RECRUITINGStony Brook Medicine Anti-Inflammatory Trial
NCT00137033PHASE4COMPLETEDCelebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population
NCT00139776PHASE4COMPLETEDStudy Of Continuous Use Of Celecoxib Vs. Usual or Intermittent Use
NCT00141102PHASE4COMPLETEDStudy Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis
NCT00174317PHASE4COMPLETEDCelecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip
NCT00177866PHASE4TERMINATEDSafety of Celecoxib in Patients With Crohn’s Disease
NCT00194090PHASE4COMPLETEDEfficacy of Celecoxib vs Placebo to Prevent Pain in a Paced Walk
NCT00261586PHASE4COMPLETEDA Safety Trial to Compare Different Analgesics in Combination With Low Dose Aspirin to Study Their Bleeding Properties and Their Effects on the Stomach
NCT00290901PHASE4COMPLETEDCelebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.
NCT00292721PHASE4COMPLETEDEffects of Celecoxib After Percutaneous Coronary Intervention
NCT00304317PHASE4WITHDRAWNCelecoxib (Celebrex) in the Management of Acute Renal Colic
NCT00346216PHASE4COMPLETEDProspective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
NCT00359151PHASE4TERMINATEDCelebrex Total Knee Arthroplasty Study
NCT00373685PHASE4COMPLETEDGI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)
NCT00446797PHASE4COMPLETEDOpen Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain
NCT00447759PHASE4COMPLETEDThe Standard Care Versus Celecoxib Outcome Trial
NCT00471341PHASE4COMPLETEDEffect of Celecoxib on Markers of Vascular Inflammation
NCT00473980PHASE4COMPLETEDPreoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients
NCT00484718PHASE4TERMINATEDMeasuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.
NCT00500279PHASE4UNKNOWNEffects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial
NCT00520338PHASE4COMPLETEDCelecoxib for Reducing Morphine Requirement After Thyroid Surgery: A Randomized Controlled Trial
NCT00565500PHASE4COMPLETEDCelecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin
NCT00598234PHASE4COMPLETEDPerioperative Pain Control With Celecoxib (Celebrex) in Total Knee Arthroplasty
NCT00620867PHASE4COMPLETEDEfficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)
NCT00624559PHASE4COMPLETEDThe Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure
NCT00630929PHASE4COMPLETEDEfficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)
NCT00633386PHASE4COMPLETEDEffect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery
NCT00633438PHASE4COMPLETEDEffect of Celecoxib Versus Placebo Before and After Knee Surgery on Overall Use of Analgesics After Surgery
NCT00638807PHASE4COMPLETEDSafety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen
NCT00640432PHASE4COMPLETEDSafety And Efficacy Of Celecoxib Versus Sodium Diclofenac In The Treatment Of Acute Low Back Pain
NCT00640627PHASE4COMPLETEDEfficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen
NCT00640809PHASE4COMPLETEDComparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole
NCT00643799PHASE4COMPLETEDSafety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis
NCT00664690PHASE4WITHDRAWNEffect of Celecoxib on Transitional Pain After Outpatient Surgery
NCT00687388PHASE4WITHDRAWNThe Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia
NCT00778193PHASE4COMPLETEDEffect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers

Clinical evidence (CIViC)

Variant × indication × effect (3 predictive associations from 3 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
COX2 OverexpressionHer2-receptor Negative Breast CancerSensitivity/ResponseCelecoxibCIViC BEID10155
PIK3CA MutationHead And Neck Squamous Cell CarcinomaSensitivity/ResponseAspirin + Sulindac + CelecoxibCIViC BEID7185
CTNNB1 T41ADesmoid TumorSensitivity/ResponseCelecoxibCIViC CEID6048

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

GuidelineSourceGene(s)DosingRecommendation
Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lCPICCYP2C9yesyes

PharmGKB also curates 6 clinical and 48 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

459 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
VALDECOXIBChEMBLPhase 4 (approved)CA12, PTGS1, PTGS2
CURCUMINChEMBLPhase 3CA12, PTGS1, PTGS2
RESVERATROLChEMBLPhase 3CA12, PTGS1, PTGS2
3,3’,4’,5-TETRACHLOROSALICYLANILIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
ACEMETACINChEMBLPhase 4 (approved)PTGS1, PTGS2
ASPIRINChEMBLPhase 4 (approved)PTGS1, PTGS2
BROMFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPSAICINChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPTOPRILChEMBLPhase 4 (approved)PTGS1, PTGS2
CARPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
CIANIDANOLChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXIBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXKETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DICLOFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)PTGS1, PTGS2
DOBUTAMINEChEMBLPhase 4 (approved)CA12, PTGS2
DOXORUBICINChEMBLPhase 4 (approved)PTGS1, PTGS2
ESFLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
ETODOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
ETORICOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
FLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
GLAFENINEChEMBLPhase 4 (approved)PTGS1, PTGS2
HEXACHLOROPHENEChEMBLPhase 4 (approved)PTGS1, PTGS2
IBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
INDAPAMIDEChEMBLPhase 4 (approved)CA12, PTGS2
INDOMETHACINChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOROLACChEMBLPhase 4 (approved)PTGS1, PTGS2
LEVODOPAChEMBLPhase 4 (approved)PTGS1, PTGS2
LOXOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
LUMIRACOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
MECLOFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MEFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MELOXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
MOFEZOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
MONOBENZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
NAPROXENChEMBLPhase 4 (approved)PTGS1, PTGS2
NIMESULIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
OMADACYCLINEChEMBLPhase 4 (approved)PTGS1, PTGS2
OXAPROZINChEMBLPhase 4 (approved)PTGS1, PTGS2
PIROXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
PRIMAQUINEChEMBLPhase 4 (approved)PTGS1, PTGS2
RANITIDINEChEMBLPhase 4 (approved)PTGS1, PTGS2
ROFECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
SELINEXORChEMBLPhase 4 (approved)PTGS1, PTGS2
SULPIRIDEChEMBLPhase 4 (approved)CA12, PTGS1
SUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
TEGASERODChEMBLPhase 4 (approved)PTGS1, PTGS2
TELOTRISTATChEMBLPhase 4 (approved)PTGS1, PTGS2
TOLMETINChEMBLPhase 4 (approved)PTGS1, PTGS2
TROGLITAZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
VORTIOXETINEChEMBLPhase 4 (approved)PTGS1, PTGS2
QUERCETINChEMBLPhase 3CA12, PTGS2
THIMEROSALChEMBLPhase 3CA12, PTGS1
CIMICOXIBChEMBLPhase 2PTGS1, PTGS2
DERACOXIBChEMBLPhase 2PTGS1, PTGS2
DITIOCARBChEMBLPhase 2CA12, PTGS1
ENOFELASTChEMBLPhase 2PTGS1, PTGS2
FIROCOXIBChEMBLPhase 2PTGS1, PTGS2
FLUFENAMIC ACIDChEMBLPhase 2PTGS1, PTGS2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot